Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial
A legfontosabb adatok
- Ki végzi
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Hol
- Kína11 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 118 fő, tervezett
- Kezdés
- 2026. máj. 1.
- Várható befejezés
- 2030. febr. 28.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Scheduled Firsekibart administration
- As-Needed Firsekibart Administration
- A regiszteradat frissítve
- 2026. június 1.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with gout who had 24 weeks of Firsekibart with no gout flares. It compares regular doses with doses given only when a flare happens.
- Életkor
- 18 to 75 years
- Nem
- Male or female
- A betegség stádiuma
- Gout meeting the 2015 ACR/EULAR Gout Classification Criteria. People must have had 2 or more gout flares in the 1 year before their first Firsekibart dose.
- Korábbi kezelés
- People must have had Firsekibart 200 mg by injection under the skin for 24 weeks, with no gout flares. People cannot join if they had steroid medicine taken by mouth or injection, or colchicine or NSAIDs, in the 24 weeks before joining. People must be willing to follow the urate-lowering treatment set by the protocol.
A részvétel fő kizáró okai
- Gout caused by another illness, rheumatoid arthritis, or a joint infection
- Cancer in the past 5 years, except some treated skin cancers
- Organ transplant, bone marrow or stem cell transplant, HIV, or other severe immune weakness
- Serious heart disease, active tuberculosis, kidney dialysis, or eGFR < 30 mL/min/1.73m²
- Pregnancy or breastfeeding
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 to 75 years (inclusive), male or female;**
- Meet the 2015 ACR/EULAR Gout Classification Criteria;**
- Received initial treatment with Firsekibart 200 mg via subcutaneous injection for 24 weeks, and experienced no gout flares during this 24-week period;**
- Had≥2 gout flares within 1 year prior to the first administration of Firsekibart;
- Willing to comply with the protocol-defined urate-lowering therapy (ULT) during the study, meeting one of the following conditions:; Patients currently receiving ULT with a stable regimen for≥14 days may continue their stable dosing; adjustments (including medication switch, dose reduction, or discontinuation) are permitted if the investigator assesses intolerance, poor efficacy, or achievement of target serum uric acid levels; For patients not on ULT or those on ULT but not stable for 14 days before enrollment, the investigator will decide whether to initiate ULT based on uric acid levels. In principle, allopurinol-naive patients should not be prescribed allopurinol in this study
- Voluntarily signed the Informed Consent Form (ICF)
Ki nem vehet részt
- Systemic treatment with corticosteroids, or use of colchicine/NSAIDs within 24 weeks prior to enrollment
- Confirmed active visceral bleeding, or severe bleeding tendency, or currently receiving anticoagulation therapy with heparin
- Presence of infection requiring systemic treatment within 7 days prior to screening
- Received live or live-attenuated vaccines within 3 months prior to screening, or planned vaccination with such vaccines during the study
- Receiving renal dialysis
- Use of any investigational drug or participation in other interventional clinical trials within 1 month prior to screening (participation in observational studies only is permitted)
- History of hypersensitivity to the study drug or similar classes of drugs
- Confirmed or suspected rheumatoid arthritis, infectious/septic arthritis, or other conditions that may confound the assessment of affected joints (e.g., other joint pain including but not limited to neurological disorders, herpes zoster, etc.)
- History of malignancy within 5 years prior to screening, except for adequately treated or excised cutaneous basal cell carcinoma or Stage I squamous cell carcinoma
- History of systemic irradiation or total lymphoid irradiation; history of stem cell therapy or any type of bone marrow transplantation; history of solid organ transplantation; or long-term systemic use of immunosuppressants
- History of severe immunodeficiency, including positive human immunodeficiency virus (HIV) antibody, or other acquired or congenital immunodeficiency diseases
- Confirmed active tuberculosis infection
- History of drug and/or alcohol abuse or psychiatric disorders
- Any other conditions that, in the opinion of the investigator, may affect the evaluation of efficacy or safety in this study
- History of clinically significant diseases, including:; Chronic congestive heart failure (NYHA Class IV); History of echocardiography-confirmed ejection fraction (EF) < 30%; Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months; Coronary revascularization within 6 months; Severe arrhythmia requiring treatment with Class Ia or III antiarrhythmic drugs; History of sick sinus syndrome, Mobitz II and Complete Heart Block without a permanent pacemaker implanted; QTc interval≥480 ms on screening ECG
- Laboratory abnormalities at screening as follows:; White blood cellcount or absolute neutrophil count below the lower limit of normal at the study site; Platelet count ≤100×10\^9/L; Total bilirubin > 1.5 times ULN (Upper Limit of Normal); AST/ALT > 3 times ULN; Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m²; Triglycerides > 5.7 mmol/L
- Confirmed secondary gout
- Pregnant or breastfeeding women
- Women of childbearing potential who refuse to use highly effective contraception during the study
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Study Objective To compare the efficacy of continued scheduled dosing versus as-needed dosing in patients with acute gouty arthritis who remained recurrence-free after 24 weeks of treatment with Firsekibart.
A teljes eredeti leírásKevesebb
Primary Endpoint The proportion of patients experiencing at least one gout recurrence within 24 weeks after randomization.
Secondary Endpoints The mean number of gout recurrences within 24 weeks after randomization;The duration of the first gout recurrence;The proportion of patients experiencing at least one gout recurrence within 12 weeks after randomization;Time to first gout recurrence after randomization;Patient treatment satisfaction at 24 weeks after randomization, assessed using a Likert scale.
Study Design and Methods Patients with acute gouty arthritis who had received Firsekibart as initial treatment and experienced no recurrence during the first 24 weeks of treatment were eligible for enrollment and randomization in this study. Eligible patients were randomized to either a scheduled dosing group or an as-needed dosing group.
In the scheduled dosing group, patients received study treatment immediately after enrollment. In the as-needed dosing group, patients entered an observation period after enrollment and received study treatment only in the event of recurrence.
During the study, gout recurrence was recorded using patient diary cards. Telephone follow-up was conducted every 4 weeks to confirm recurrence status. On-site visits were performed at Weeks 12 and 24, as well as at the time of gout recurrence, for collection of efficacy-related assessments. Adverse events (AEs) and serious adverse events (SAEs) were followed until 12 weeks after the last dose of study drug.
Treatment Arms Scheduled Dosing Group (Intervention Group): Firsekibart 200 mg was administered by subcutaneous injection on the day of randomization.
As-Needed Dosing Group (Control Group): Patients were observed after randomization. If recurrence occurred, patients were required to return to the hospital within 4 days and receive Firsekibart 200 mg by subcutaneous injection.
A vizsgálat 2 csoportja
- Regular dosing groupA vizsgált kezelés
Kezelés: Scheduled Firsekibart administration
- On-demand dosing groupEgyéb csoport
Kezelés: As-Needed Firsekibart Administration
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07616531: ki vehet részt
- A regiszteradat frissítve
- 2026. június 1.